Advertisement

Phage Therapy and the Future

  • Milton W. TaylorEmail author
Chapter
  • 2.1k Downloads

Abstract

Who really discovered bacteriophage? Ernest Hankin, a British scientist working in India in the nineteenth century, claimed that the lack of bacterial contamination in the Ganges River was due to the presence of anti-bacterial substance. The idea of using phage to counteract bacterial infections was promoted by Felix d’Herelle. In the 1930s there were large, successful clinical trials in the U.S. using phage to counteract carbuncles and other infections. The pharmaceutical company Eli Lilly advertised the sale of bacteriophage to counteract various bacterial infections, mistakenly including herpes. Phage therapy was accepted in Eastern Europe and the Soviet Union from 1930 until the 1950s, with phage being used to treat dysentery among soldiers in World War II. There was a decline in its use with the collapse of the Soviet Union, but phage therapy is actively being investigated as a treatment to prevent food spoilage, and as a veterinary medicine, and the time is ripe to begin phage therapy clinical trials in the West. There is renewed interest in phage therapy because of the high risk of antibiotic-resistant strains of bacteria.

Keywords

Hemolytic Uremic Syndrome Phage Therapy Lytic Phage Phage Resistance Phage Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hankin, M. E. (1896). The bactericidal actions of the waters of the Jamuna and Ganges River on cholera microbes. BrMedJ 1.Google Scholar
  2. 2.
    Hankin, M. E. (1898). Cholera in Indian villages. BrMedJ 3.Google Scholar
  3. 3.
    BRaM, J. (1921). Au sujet del’unite du principe bacteriophage. Comptes Rendus Acad Sci de Biol, 85, 1122.Google Scholar
  4. 4.
    Chanishvili, N. (2012). Phage therapy–history from Twort and d’Herelle through soviet experience to current approaches. Advances in Virus Research, 83, 3–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Rice, T. B. (1930). The use of bacteriophage filtrates in the treatment of suppurative conditions: Report on 300 cases. American Journal Medical Sciences, 179, 345–360.CrossRefGoogle Scholar
  6. 6.
    Stout, B. F. (1933). Bacteriophage therapy. Texas State Journal Medicine, 29, 205–209.Google Scholar
  7. 7.
    Hausler, T. (2006). Viruses versus, superbugs. Macmillan: Basingstoke. What city?Google Scholar
  8. 8.
    Sulakvelidze, A., Alavidze, Z., & Morris, J. G, Jr. (2001). Bacteriophage therapy. Antimicrobial Agents and Chemotherapy, 45(3), 649–659.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Weber-Dabrowska, B., Dabrowski, M., & Slopek, S. (1987). Studies on bacteriophage penetration in patients subjected to phage therapy. Archivum Immunologiae et Therapiae Experimentalis, 35(5), 563–568.PubMedGoogle Scholar
  10. 10.
    Smith, H. W., & Huggins, M. B. (1982). Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. Journal of General Microbiology, 128(2), 307–318.PubMedGoogle Scholar
  11. 11.
    O’Flaherty, S., Ross, R. P., & Coffey, A. (2009). Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiology Reviews, 33(4), 801–819.PubMedCrossRefGoogle Scholar
  12. 12.
    Kutateladze, M., & Adamia, R. (2010). Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends in Biotechnology, 28(12), 591–595.PubMedCrossRefGoogle Scholar
  13. 13.
    Stone, R. (2002). Bacteriophage therapy. Stalin’s Forgotten Cure. Science, 298(5594), 728–731.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Indiana UniversityBloomingtonUSA

Personalised recommendations